Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study

Area of Science:

• Gastroenterology
• Infectious Diseases
• Epidemiology

Background:

• Inflammatory bowel disease (IBD) encompasses chronic conditions like Crohn's disease and ulcerative colitis.
• Clostridium difficile infection (CDI) is a significant concern in healthcare settings, particularly for vulnerable populations.
• Understanding CDI epidemiology in IBD patients is crucial for effective management and prevention.

Purpose of the Study:

• To investigate the epidemiology of Clostridium difficile infections (CDI) in patients with inflammatory bowel disease (IBD).
• To identify risk factors associated with CDI development in the IBD population.
• To compare characteristics of IBD patients with and without CDI.

Main Methods:

• Retrospective study analyzing charts of 654 IBD patients meeting inclusion criteria.
• Patients divided into two cohorts: those with and without a prior CDI diagnosis.
• Statistical analyses included Pearson's chi-squared and two-sample t-tests.

Main Results:

• The incidence of CDI among IBD patients was 6.7%.
• CDI prevalence was similar in Crohn's disease (49%) and ulcerative colitis (51%) patients.
• IBD patients acquired CDI at a mean age of 42.7 years, with community acquisition (56%) more common than healthcare-associated (28%).
• Traditional risk factors like prior antibiotic (30%) and steroid use (16%) were less frequent.
• IBD patients with CDI were more likely to require biologic therapy (57% vs. 37%) and have extraintestinal manifestations (43% vs. 28%).

Conclusions:

• IBD patients are susceptible to CDI at a younger age and often lack traditional risk factors.
• IBD patients with CDI demonstrated increased need for biologic therapy.
• Higher rates of extraintestinal manifestations were observed in IBD patients with CDI.